pre-update Archives

On-Demand Webinar

FDA Modernization Act 2.0 – What does it mean for drug developers?

Historically, the FDA has required drug discovery and development programs to include animal testing. This…

CertaraFebruary 21, 2023

On-Demand Webinar

RAPS Sponsored: How Drug Developers Can Navigate the Inflation Reduction Act

The Inflation Reduction Act (enacted in August 2022) contains profound changes for the healthcare and…

CertaraFebruary 10, 2023

On-Demand Webinar

Data Visualization with SEND Data to See What Happened at the Preclinical Phase

SEND is an implementation of CDISC’s (Clinical Data Interchange Standards Consortium) SDTM (Study Data Tabulation…

CertaraFebruary 9, 2023

White Paper

A Guide to the UK Regulation of Medicines and Medical Devices Post-Brexit

CertaraFebruary 8, 2023

Podcast

Podcast interview with Dr. Elvira Müller. EU joint HTA – decided, but how will it be executed and how should companies prepare

In Europe, there are at least as many reimbursement assessment processes in place as European…

CertaraFebruary 7, 2023

Announcement

FDA awards new grants to support developing & assessing complex generic drugs

Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator is being used to verify and expand biosimulation models…

CertaraFebruary 7, 2023

Blog

Artificial Intelligence: What is it & how can it accelerate rare disease drug development?

Large & complex information streams present opportunities for the AI data scientist to aid in…

CertaraFebruary 3, 2023

On-Demand Webinar

Machine learning model selection with Darwin in Pirana

Discover how to enhance machine learning model selection with Darwin in Pirana. Watch this on-demand…

CertaraFebruary 3, 2023

White Paper

Certara’s combined PBPK/QSP model predicts safety and efficacy biomarker outcomes in Alzheimer’s Disease, as demonstrated in recent lecanemab work with Eisai

CertaraFebruary 2, 2023

Press Release

Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1^st, 2023

PRINCETON, N.J.— February 1, 2023-- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today…

CertaraFebruary 1, 2023

pre-update

FDA Modernization Act 2.0 – What does it mean for drug developers?

RAPS Sponsored: How Drug Developers Can Navigate the Inflation Reduction Act

Data Visualization with SEND Data to See What Happened at the Preclinical Phase

A Guide to the UK Regulation of Medicines and Medical Devices Post-Brexit

Podcast interview with Dr. Elvira Müller. EU joint HTA – decided, but how will it be executed and how should companies prepare

FDA awards new grants to support developing & assessing complex generic drugs

Artificial Intelligence: What is it & how can it accelerate rare disease drug development?

Machine learning model selection with Darwin in Pirana

Certara’s combined PBPK/QSP model predicts safety and efficacy biomarker outcomes in Alzheimer’s Disease, as demonstrated in recent lecanemab work with Eisai

Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1^st, 2023

Newsletter sign up

Quick links

Solutions

Contact